Roche to cut 4,800 jobs; pharma mainly hit
This article was originally published in Clinica
Executive Summary
Roche is to cut 4,800 jobs, or 6% of its global workforce, in a CHF2.4bn ($2.4bn) annual cost-cutting plan to offset pricing pressures and a "more challenging market environment", it said. The restructuring plan, called Operational Excellence, will mostly affect the pharmaceutical division – particularly in sales and marketing (2,650 jobs cut) and manufacturing (1350 jobs cut) – and lead to restructuring costs of about CHF2.7 billion over the next two years. The programme is expected to generate savings of CHF1.8 billion in 2011 and CHF2.4 billion from 2012 onwards. In addition to the planned job cuts, the company expects to transfer 800 jobs internally and about 700 positions to "third parties". About 6,300 jobs will be affected overall, with most of the reductions in the US.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.